News Roche raises outlook for 2017 following strong launches The launch of three new products with blockbuster potential helped increase Roche’s revenues 5% in
Views & Analysis ASCO 2017: Breast cancer next target for Keytruda Immunotherapy combinations will be the focus - but attention is shifting towards these agents proving their overall survival benefits.
News BMS looks to Opdivo + vaccine combo for non-PD-L1 lung cance... Bristol-Myers Squibb is teaming up with France’s Transgene to combine Opdivo with investigational therapeutic vaccine TG4010 in lung cancer.
News Roche’s Alecensa beats Xalkori in lung cancer head-to-head Roche’s new targeted lung cancer treatment Alecensa has shown itself to be superior to Pfizer’s established rival Xalkori in a head-to-head trial as a first line treatment.
News Novartis' Zykadia gets fast first-line lung cancer review Roche rival has Breakthrough Therapy status.
News Roche’s Alecensa approved in Europe, with head-to-head data ... Alecensa part of Roche's goal of becoming dominant player in NSCLC
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
